Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

This sale reduced an insider's direct equity holdings by 11%.

This sale reduced an insider's direct common stock position by 27%, though a majority of the position remains held through trusts and spousal holdings.

Tarr reduced his direct equity stake but retains roughly 268,000 shares valued at $33.7 million.

Encompass Health’s second quarter reflected robust demand for inpatient rehabilitation, with the company delivering revenue growth above Wall Street expectations and a double-digit gain in non-GAAP earnings per share. Management attributed the strong results to ongoing investments in clinical workforce development and capacity additions, as well as continued momentum in treating higher-acuity patient categories like stroke and brain injury. CEO Mark Tarr highlighted that the company’s patient ou

Revenue hit $1.597 billion with adjusted EPS up 10.7% as occupancy improved.

LifeStance Health (LFST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AVAH's Q2 revenues are expected to rise 9.8%, but lower PDS margins and higher costs may weigh on earnings.

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

Health care services provider Encompass Health (NYSE:EHC) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.6% year on year to $1.60 billion. The company expects the full year’s revenue to be around $6.45 billion, close to analysts’ estimates. Its non-GAAP profit of $1.55 per share was 4.7% above analysts’ consensus estimates.

Encompass Health (EHC) shares are in focus after the company reported second quarter revenue of about US$1.6b and earnings per share of US$1.55, both above analyst expectations, alongside higher full year 2026 revenue guidance. See our latest analysis for Encompass Health. At a share price of US$125.23, Encompass Health has a 7 day share price return of 12.75% and a 90 day share price return of 18.03%. Its 3 year total shareholder return of 80.09% points to momentum that has been building...

Encompass Health stock has delivered a 110.2% total return over the past 5 years, and at a recent price of US$125.23 the valuation checks now matter more than ever, especially since both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings based multiples currently point to the shares trading below their assessed worth. Over 5 years, Encompass Health has returned 110.2% to shareholders, which puts current buyers in the position of asking whether the latest price still...

Encompass Health (NYSE:EHC) reported second-quarter 2026 results marked by revenue, earnings and discharge growth, prompting the inpatient rehabilitation provider to raise its full-year outlook. Revenue increased 9.6% from the prior-year quarter, while adjusted EBITDA rose 9.2% to $348 million and

EHC beats Q2 earnings estimates as higher patient revenues and strong discharge growth drive results, leading the company to raise its 2026 adjusted EPS outlook.

Moby summary of Encompass Health Corporation's Q2 2026 earnings call

The headline numbers for Encompass Health (EHC) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Encompass Health (EHC) delivered earnings and revenue surprises of +4.73% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Health care services provider Encompass Health (NYSE:EHC) announced better-than-expected revenue in Q2 CY2026, with sales up 9.6% year on year to $1.60 billion. The company expects the full year’s revenue to be around $6.45 billion, close to analysts’ estimates. Its non-GAAP profit of $1.55 per share was 4.7% above analysts’ consensus estimates.

EHC's higher occupancy, rising discharges and hospital expansion could support Q2 growth, but can they offset mounting operating costs?

McKesson, Encompass Health and Omega Healthcare Investors raised dividends, with payout ratios and yields showing varying levels of sustainability across the healthcare sector.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Encompass Health (NYSE:EHC) and the rest of the outpatient & specialty care stocks fared in Q1.

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

Madison Small Cap Fund, managed by Madison Funds, released its Q2 2026 investor letter. A copy of the letter can be downloaded here. The small-cap market showed exceptional strength in Q2, largely due to anticipated peace in the Middle East. The Russell 2000 Index began to rally, propelled by Information Technology, Health Care, and Industrials. The […]